EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 296 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Today is Veterans Day November 11, 2020 Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... March 1, 2024 Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents July 10, 2018 A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... July 11, 2024 Load more HOT NEWS Five Questions with…Jennifer. New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... NICE doesn’t recommend olaparib for patients with certain prostate cancers 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks...
